A phase I trial of CORT125281 as a potential treatment for castration-resistant prostate cancer.

Trial Profile

A phase I trial of CORT125281 as a potential treatment for castration-resistant prostate cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs CORT 125281 (Primary) ; Enzalutamide
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Nov 2017 According to a Corcept Therapeutics media release, the study has been initiated in healthy subjects. Dose ranging in combination with Xtandi (enzalutamide) in patients with castration-resistant prostate cancer is expected to start this quarter.
    • 02 Nov 2017 Status changed from planning to recruiting, according to a Corcept Therapeutics media release.
    • 01 Aug 2017 According to a Corcept Therapeutics media release, the dose-ranging trial of CORT125281 combined with Xtandi will be studied in healthy subjects this quarter and in patients with castration-resistant prostate cancer next quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top